Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1316Neoplasms 1104Carcinoma, Non-Small-Cell Lung 916Prostatic Neoplasms 747Colorectal Neoplasms 645Lung Neoplasms 621Neoplasm Metastasis 470Multiple Myeloma 444Leukemia, Myeloid, Acute 440Pancreatic Neoplasms 392Ovarian Neoplasms 388Melanoma 346Carcinoma, Hepatocellular 308Brain Neoplasms 290Squamous Cell Carcinoma of Head and Neck 285Recurrence 285Glioblastoma 260Stomach Neoplasms 252Head and Neck Neoplasms 250Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Carcinoma, Renal Cell 237Lymphoma 235Triple Negative Breast Neoplasms 233Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Hematologic Neoplasms 216Urinary Bladder Neoplasms 212Lymphoma, Non-Hodgkin 203Glioma 202Sarcoma 200

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × 90 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡